Mascarilla N95 Niosh

Información básica

• Disponible en:
• English
• Español

The EarlyTect Colon Cancer Test is a highly reliable diagnostic tool that has been approved by the Korea Ministry of Food and Drug Safety. It has been extensively tested at reputable medical centers such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. The clinical trials involved 585 men and women aged 30 to 80 who were eligible subjects for the study.

Through these trials, it has been shown that the EarlyTect Colon Cancer Test is able to diagnose colorectal cancer (CRC) with an impressive 90% sensitivity and specificity. The test utilizes a qualitative real-time PCR technique to measure the presence of methylated Syndecan-2, which is a biomarker clinically associated with precancerous lesions of CRC. By analyzing stool DNA, the EarlyTect test can effectively identify the presence of colorectal cancer.

It is important to note that the EarlyTect Colon Cancer Test is not designed to confirm the presence of colorectal cancer. Instead, it is a valuable tool for screening and detecting potential cases of CRC or precancerous lesions of CRC. This early detection can be vital in preventing the progression of the disease and improving treatment outcomes.

The product standard of the EarlyTect Colon Cancer Test includes the following specifications:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: Syndecan-2 methylation (SDC2 mer)

The price and transaction conditions for the EarlyTect Colon Cancer Test are open to negotiation. To learn more about the pricing and initiate a transaction, we encourage you to request a quote.